Respiratory Dysbiosis in Preschool Children with Asthma: Predictive of a Severe Form
Recruiting · NCT05192499 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Brest
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The prevalence of asthma in preschool children is between 11 and12%. Inhaled corticosteroid therapy is the main therapy used, however this treatment seems insufficiently effective in some children. Recent research in cystic fibrosis has made it possible to highlight pulmotypes corresponding to the different stages of pulmonary dysbiosis, and a predictive microbiological signature of an increased risk of early primocolonization to P. aeruginosa. These pulmotypes are the result of the so-called "enterotyping" analysis, a biostatistical method that makes it possible to stratify individuals according to the analysis of the microbiota. In the light of these data, it seems interesting to transcribe the concept of using a biomarker of the microbiota in the monitoring of a chronic lung disease such as asthma. The hypothesis is that there is respiratory dysbiosis causing corticosteroid resistance to treatment in children under 3 years of age with severe asthma.
Who can take part
Inclusion criteria
- Age greater than 1 year and less than 3 years
- Diagnosis of asthma by a pediatrician
- Parental consent
- Affiliation to the social security system
Exclusion criteria
- Chronic pathologies: congenital heart disease, immune deficiency, cystic fibrosis, bronchopulmonary dysplasia, encephalopathy, primary ciliary dyskinesia, laryngomalacia, digestive pathology requiring digestive surgery
- Premature \< 34 SA
- Recent antibiotic therapy (\< 7 days)
- Treatment with oral corticosteroid therapy within the previous 10 days.
- Patient whose parent(s) is (are) minor(s)
Where it is running
1 location listed.
- CHU de Brest - Brest, Finistère, France